相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
Petros Fessas et al.
IMMUNOLOGY (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients
J. Rogado et al.
EUROPEAN JOURNAL OF CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
Naoto Okada et al.
CLINICAL THERAPEUTICS (2019)
Involvement of CCL2/CCR2 macrophage recruitment in amodiaquine-induced liver injury
Alastair Mak et al.
Journal of Immunotoxicology (2019)
Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans
Anita K. McElroy et al.
EMERGING INFECTIOUS DISEASES (2019)
Deletion of PTPN22 improves effector and memory CD8+ T cell responses to tumors
Rebecca J. Brownlie et al.
JCI INSIGHT (2019)
CD14+ CD15- HLA-DR- myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure
Christine Bernsmeier et al.
GUT (2018)
MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure
Evangelos Triantafyllou et al.
GUT (2018)
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
Oliver Krenkel et al.
HEPATOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
Eleonora De Martin et al.
JOURNAL OF HEPATOLOGY (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
Taku Fujimura et al.
Oncotarget (2018)
Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase
Nikhil Vergis et al.
GUT (2017)
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury
Jana C. Mossanen et al.
HEPATOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis
D. M. Foureau et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Treatment of PD-1-/- Mice With Amodiaquine and Anti-CTLA4 Leads to Liver Injury Similar to Idiosyncratic Liver Injury in Patients
Imir G. Metushi et al.
HEPATOLOGY (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study
E. S. Andersen et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2014)
T cell-intrinsic role of IL-6 signaling in primary and memory responses
Simone A. Nish et al.
ELIFE (2014)
The who's who of T-cell differentiation: Human memory T-cell subsets
Yolanda D. Mahnke et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
EBI2 Is a Negative Regulator of Type I Interferons in Plasmacytoid and Myeloid Dendritic Cells
Eugene Y. Chiang et al.
PLOS ONE (2013)
Increased CD163 expression is associated with acute-on-chronic hepatitis B liver failure
Hong Ye et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Functional heterogeneity of human effector CD8+ T cells
Hiroshi Takata et al.
BLOOD (2012)
Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans
Charalambos Gustav Antoniades et al.
HEPATOLOGY (2012)
The three human monocyte subsets: implications for health and disease
Kok Loon Wong et al.
IMMUNOLOGIC RESEARCH (2012)
Cd81 Interacts with the T Cell Receptor to Suppress Signaling
Safak Isil Cevik et al.
PLOS ONE (2012)
Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets
Kok Loon Wong et al.
BLOOD (2011)
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Nicole Joller et al.
JOURNAL OF IMMUNOLOGY (2011)
Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients
Tricia H. Burdo et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer-Preclinical Background: CTLA-4 and PD-1 Blockade
Jeffrey Weber
SEMINARS IN ONCOLOGY (2010)
Hepatic Recruitment of the Inflammatory Gr1+ Monocyte Subset Upon Liver Injury Promotes Hepatic Fibrosis
Karlin Raja Karlmark et al.
HEPATOLOGY (2009)
Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function
Mario-Ernesto Cruz-Munoz et al.
NATURE IMMUNOLOGY (2009)
Cloning, eukaryotic expression of human ISG20 and preliminary study on the effect of its anti-HBV
Youltua Hao et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2008)
Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus
Dong Jiang et al.
JOURNAL OF VIROLOGY (2008)
ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses
L Espert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene
JJ Gu et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
